AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06306287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePACE Personalized Intervention
Description: The ePACE intervention is based on culturally and developmentally relevant youth treatments organized around an integrative approach based on Motivational Enhancement Therapy (MET) and Cognitive Behavior Therapy (CBT) to enhance motivation for change, support awareness of thoughts, emotions, and behavior, and address specific behavior change goals. The web-based approach is personalized, with youth-driven choices in terms of intensity, content, and sequencing of content and provide tailored feedback to youth regarding each individual's behavior change efforts. Modules address substance use, negative moods, decision-making, and interpersonal relations and require approximately 40-minutes to complete. Interactive activities, exercises, and quizzes are designed to promote skill acquisition. Each module involves an introduction and engagement strategies, several exercises and activities related to the problem area, goal setting, and a summary.
Study NCT06306287 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eFACE Fixed Intervention
Description: The eFACE intervention includes content that is similar to ePACE, but modules are offered in a fixed order with no tailoring features. Like ePACE, modules address substance use, negative moods, decision-making, and interpersonal relations and require approximately 40-minutes to complete. Each module involves an introduction and engagement strategies, several exercises and activities related to the problem area, goal setting, and a summary. However, no personalized feedback based on youth responses are provided to inform individual youth's behavior change efforts.
Study NCT04354545 — intervention group
Intervention type: DRUG
Intervention: Xiidra (Lifitegrast ophthalmic solution) 5%
Description: FDA approved lifitegrast opthalmic solution eye drop
Study NCT04646681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ConnectCare
Description: increased monitoring between clinical mental health visits
Study NCT06476236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: M4C
Description: Nutraceutical designed to enhance novel metabolic pathway activity.
Study NCT04792567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: taken orally once per day (dose depends on CYP2C9 genotype)
Study NCT04792567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline disease modifying therapies (DMTs)
Description: DMTs: Dimethylfumarate, glatirameracetate, interferon, teriflunomode according to respective SmPC
Study NCT04792567 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162
Description: Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study.
Study NCT04792567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162
Description: Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study.
Study NCT04792567 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study
Study NCT04792567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study
Study NCT05425914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: New treatment option for dry eye patients with low serum vitamin D Level
Study NCT05425914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tear
Description: Conventional dry eye treatment
Study NCT05425914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial tear
Description: Conventional dry eye treatment
Study NCT05131984 — intervention group
Intervention type: DRUG
Intervention: Ocrelizumab
Description: At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year
Study NCT06432829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for the transdiagnostic treatment of emotional disorders
Description: This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups at 1 and 3 months after the end of the treatment.
Study NCT06432829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol for the transdiagnostic treatment of emotional disorders
Description: This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups at 1 and 3 months after the end of the treatment.
Study NCT06471426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: The following methods of evaluation and treatment will be utilized on all subjects: Indirect myofascial release to the cervical region, osteopathic cranial manipulation, sacral articular technique.
Study NCT04822610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interscalene block
Description: peripheral nerve block
Study NCT04822610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suprascapular block + axillary block
Description: peripheral nerve block
Study NCT04782011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATC/DDD
Description: The intervention is the introduction of the ATC/DDD including the training on its importance and usage in monitoring antibiotic use at a given primary care facility.
Study NCT05024799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl, propofol
Description: The patients in this group will be administered with fentanyl and propofol
Study NCT05024799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl and dexmedetomindine
Description: The patients in this group will be administered with fentanyl and dexmedetomindine
Study NCT05024799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol and propofol
Description: The patients in this group will be administered with butorphanol and propofol
Study NCT05024799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol and dexmedetomindine
Description: The patients in this group will be administered with butorphanol and dexmedetomindine
Study NCT04869163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-red meat
Description: Red meat analogues and alternatives
Study NCT04869163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-red meat
Description: Red meat analogues and alternatives
Study NCT05560282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Description: FINTEPLA oral solution contains 2.2 mg/mL fenfluramine, equivalent to 2.5 mg/mL of the hydrochloride salt. The active ingredient, fenfluramine hydrochloride, is designated chemically as N-ethyl-α- methyl-3-(trifluoromethyl) phenethylamine hydrochloride.~Fenfluramine hydrochloride is a white to off-white crystalline solid. The pKa of fenfluramine is 10.2. FINTEPLA is a clear, colorless solution, pH 5.
Study NCT04666350 — intervention group
Intervention type: OTHER
Intervention: Direct Skin Feeding Assay (DSFA)
Description: In the direct feeding assay a cup with 60 unfed, sterile insectary-reared Anopheles gambiae mosquitoes will be allowed to feed on a participant's calf or arm for 15 minutes.
Study NCT04666350 — intervention group
Intervention type: DRUG
Intervention: Primaquine
Description: Participants will receive one dose of primaquine 26.3 mg tablet on Day 2 after completion of the direct feeding assay.
Study NCT04666350 — intervention group
Intervention type: DRUG
Intervention: Artemether/Lumefantrine
Description: Participants will receive artemether (80 mg) and lumefantrine (480 mg) combination tablets twice a day for 3 days, starting after completion of the direct feeding assay on Day 2.
Study NCT05800340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg Q3W
Study NCT05800340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 135 mg/m2, d1, 8 Q3W
Study NCT05800340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2, d1 Q3W
Study NCT05800340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5, d1 Q3W
Study NCT05126472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD40 antibody 2141-V11
Description: Cohort A Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points.
Study NCT05126472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD40 antibody 2141-V11
Description: Cohort B Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection once every 3 weeks (weeks 1, 4, 7, and 10) for a total of 4 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once every 3 weeks for a total of 4 doses) at these time points.
Study NCT05126472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD40 antibody 2141-V11
Description: Cohort C Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection as a single 10mg during standard of care cystoscopy and examination prior to and within 4 weeks of planned radical cystectomy.
Study NCT06386965 — intervention group
Intervention type: OTHER
Intervention: taking blood sample
Description: A blood sample will be taken from the patients for 3 times to evaluate the stress inflammatory markers.
Study NCT06466538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: intracanal medicament
Study NCT06466538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leddermix
Description: Leddermix
Study NCT06466538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boswellia
Description: Boswellia
Study NCT06374875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metabolic surgery
Description: Patients receive either RYGB or SG. The surgical risk, differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure
Study NCT06374875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incretin-Based Therapy
Description: Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group. Any of these 3 medications (in the injection or oral from) based on availability in each country, access, and clinical indications can be used. If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection or Ozempic 2 mg once weekly injection). Other acceptable, less preferrable, options: liraglutide (Saxenda or Victoza), semaglutide tablet (Rybelsus), or lower dose of tirzepatide and semaglutide injections.
Study NCT05948475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinengotinib 8 mg
Description: Subjects randomized to receive tinengotinib will receive a starting dose of either 8 mg QD., self-administered orally QD in 28-day cycles.
Study NCT05948475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinengotinib 10 mg
Description: Subjects randomized to receive tinengotinib will receive a starting dose of either10 mg QD., self-administered orally QD in 28-day cycles.
Study NCT05948475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice
Description: For subjects receiving FOLFOX or FOLFIRI, the subject will receive treatment every two weeks, with two administrations per each 28-day cycle.
Study NCT05891340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle exercise
Description: respiratory muscle exercise with inspiratory muscle trainer (two times a day)
Study NCT05891340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance exercise
Description: walking exercise 5000 steps/day
Study NCT04667000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forced Air Warming
Description: We will use Forced Air Warming for cesarean patient
Study NCT05538520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Pilates
Description: This group will perform a traditional Pilates session, which consists of stretching exercises, followed by exercises to strengthen the core (trunk flexors and extensors), lower limbs and upper limbs. The total duration of the intervention in this group should be approximately 50 minutes.
Study NCT05538520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates without stretching
Description: This group will conduct a non-traditional Pilates session. This is because stretching exercises will be excluded. The muscle strengthening exercises will be the same as in the TP group, so that it is possible to discuss the influence of the inclusion/exclusion of stretching for the considered outcomes. The total duration of the intervention in this group should be approximately 35 minutes.
Study NCT06010771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to fairy tales
Description: Fairy tales by children will be chosen by child psychologists. Tales will be read to the children by the researcher. The researcher has a fairy tale therapy certificate. The tale reading will start 5 minutes before the aspiration process and will continue throughout the aspiration process. Tales will be read to children every other day. This process will continue for 3 weeks.
Study NCT06010771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watching Cartoon Film
Description: The cartoons that children will watch will be preferred by child psychologists. Children will be watched cartoons with the help of tablets. Watching cartoons will start 5 minutes before the aspiration process and will continue throughout the aspiration process. Children will be shown cartoons every other day. This process will continue for 3 weeks.
Study NCT06057584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: somatosensory-motor integration training
Description: Participants will use both hands to perform functional tasks requiring somatosensory discrimination to provide different somatosensory stimuli to facilitate motor control. The experimental group will receive somatosensory-motor integration training, 3-5 sessions a week, for a total of 15 sessions.
Study NCT06057584 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pure somatosensory training
Description: Participants will use the affected hand to perform somatosensory discrimination tasks, including limb position discrimination and object discrimination.The experimental group will receive pure somatosensory integration training, 3-5 sessions a week, for a total of 15 sessions.
Study NCT06057584 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pure motor training
Description: Participants will conduct bilateral task-oriented training, but the training task does not require somatosensory discrimination. Each round only uses the same target and target position to repeatedly practice the functional task movements, but the target or target position is different in different rounds. The experimental group will receive pure motor integration training, 3-5 sessions a week, for a total of 15 sessions.
Study NCT06273670 — intervention group
Intervention type: OTHER
Intervention: screening and data collection
Description: Structured questionnaire prepared in English and translated to local language (Arabic). The questionnaire is then linguistically validated by two forwards translations and one backward translation. Data was collected by the investigators who were not participating in the study.~Personal or telephone interview will be conducted with clients and service providers conducted to collect the data.
Study NCT05380258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress ball
Description: Pregnant women with 4-5 cm cervical dilatation were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes when their contractions came, and when the cervical opening was 6-8 cm, they were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes.
Study NCT05380258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing gum
Description: Pregnant women with 4-5 cm cervical dilatation were asked to squeeze the ball for 5 seconds and loosen it for 2 seconds as soon as their contractions came and within 20 minutes, and when the cervical opening was 6-8 cm, they chewed gum again for 20 minutes.
Study NCT05529849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCMCB07
Description: Subcutaneous injection of TCMCB07
Study NCT05529849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching subcutaneous placebo
Study NCT04333745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled Diet
Description: Participant will consume a controlled low oxalate diet for five days
Study NCT04333745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbon-13 Oxalate and Sucralose Ingestion
Description: Subjects will ingest a small amount of carbon-13 oxalate and sucralose, dissolved in water.
Study NCT05752877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Targeted IL-13 Rα2 UCAR-T cell injection
Description: local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.
Study NCT05752877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Targeted B7-H3 UCAR-T cell injection
Description: local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.
Study NCT05676619 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3D foot scanner
Description: Reliability of 3D foot scanner during repeated scans
Study NCT06360991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Description: The DBS lead is stereotactically introduced into the target in the brain (vALIC, BNST, amSTN, VC/VS, or NAc) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
Study NCT05738811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS treatment protocol
Description: The 2 sets of electrodes of TENS were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot.
Study NCT05738811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMS treatment protocol
Description: The electrodes were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot. A portable comfy EMS channel was used to apply EMS protocol to set at threshold of muscle contraction level.
Study NCT05738811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Patient were given 30 minutes treatment session, 10 minutes of supported walking 10 minutes of BWS treadmill training 10 minutes of Task-specific over ground locomotor training (LT) There was rest of 2 minutes The frequency of the sessions was five times a week for 12 weeks.
Study NCT05629429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300mg BID PO
Study NCT05629429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug
Description: Continue platinum based chemotherapy